Clinical Trials
15 trialsNCT06607692 2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
NCT02834013 2026-06-03
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07621146 2026-06-02
NET-COMPARE
British Columbia Cancer Agency
Not yet recruiting
NCT04924075 2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06503146 2026-05-19
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05636618 2026-05-14
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Perspective Therapeutics
Phase 1/2 Recruiting
NCT04394858 2026-05-13
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03583528 2026-05-12
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
Active not recruiting
NCT06479811 2026-04-28
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT03206060 2026-04-24
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07538791 2026-04-24
PRRT-PGL-PHEO
Azienda USL Reggio Emilia - IRCCS
Not yet recruiting
NCT03050268 2026-04-23
SJFAMILY
St. Jude Children's Research Hospital
Recruiting
NCT07516275 2026-04-07
Prospective Cohort Study of Pheochromocytoma/Paraganglioma
Peking Union Medical College Hospital
Not yet recruiting
NCT06041516 2026-03-27
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting